FDADrugDevFC Flashcards

1
Q

What is CDER?

A

The Center for Drug Evaliation and Research is the part of FDA that oversees the drug approval process.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does the drug approval process begin?

A

Pre-clinical (animal) research which is followed by an IND application.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is an IND application?

A

It is an Investigational New Drug application required by FDA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why is an IND needed?

A

Federal laws requires that application in place before a drug is transported or distributed across states lines.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why is it important to the manufacturers to have an IND issued?

A

In order to be able to ship the investigational drug to clinical investigators in many states, the manufacturers need an exempt from that requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the focus of the phase I in the clinical trial process?

A

Safety profile and dosing range. Pharmacology of compound.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How does the phase I in the clinical trial process is conducted?

A

Low doses of the compound are given to a small group (20-80 subjects) of healthy volunteers who are closely supervised. In cases of severe or life-threatening illness, volunteers with the disease may be used.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the focus of the phase II in the clinical trial process?

A

Effectiveness of a compound (dose response).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does the phase II in the clinical trial process is conducted?

A

To avoid unnecessarily exposing a human volunteer to a potentially harmful substance, studies are based on an analysis of the fewest volunteers needed to provide sufficient statistical power to determine efficacy. Used in intended population only.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the purpose of the phase III in the clinical trial process?

A

Test safety and efficacy at the dose and schedule you are seeking approval (package labeling). During this phase, researches try to confirm previous findings in a larger population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does the phase III in the clinical trial process is conducted?

A

These studies are tested in subjects with indication only and usually involve thousands of patients across multiple sites.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What happens after Phase III?

A

The manufacturer files a New Drug Application (NDA) that can be either approved or rejected. In the case of rejection, the FDA might request further study before making a decision.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is a post-marketing study?

A

It’s the phase IV that examines the risks and benefits of the new drug in a different population or to conduct special monitoring in a high-risk population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the purpose of the Phase IV in a clinical trial?

A

It can be used to asses such issues as the longer term effects of drug exposure, to optimize the dose for marketing, to evaluate the effect in pediatric patients or to examine the effectiveness of the drug for additional indications.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What application is required by FDA to request approval of a generic drug?

A

Abbreviated New Drug Application (ANDA).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What application is required by FDA to request changes to an existing drug?

A

Supplemental New Drug Application (SNDA).

17
Q

What type of changes can be made to an existing drug?

A

Labeling changes, new dose, new strength, new manufacturing process.